Hervé Decousus, MD; Isabelle Quéré, MD; Emilie Presles, MD; François Becker, MD; Marie-Thérèse Barrellier, MD; Myriam Chanut, MD; Jean-Luc Gillet, MD; Hervé Guenneguez, MD; Christine Leandri, MD; Patrick Mismetti, MD, PhD; Olivier Pichot, MD; Alain Leizorovicz, MD; POST (Prospective Observational Superficial Thrombophlebitis) Study Group
Decousus H, Quéré I, Presles E, Becker F, Barrellier M, Chanut M, et al. Superficial Venous Thrombosis and Venous Thromboembolism: A Large, Prospective Epidemiologic Study. Ann Intern Med. 2010;152:218-224. doi: 10.7326/0003-4819-152-4-201002160-00006
Download citation file:
Published: Ann Intern Med. 2010;152(4):218-224.
Superficial venous thrombosis (SVT) is perceived to have a benign prognosis.
To assess the prevalence of venous thromboembolism in patients with SVT and to determine the 3-month incidence of thromboembolic complications.
National cross-sectional and prospective epidemiologic cohort study. (ClinicalTrials.gov registration number: NCT00818688)
French office- and hospital-based vascular medicine specialists.
844 consecutive patients with symptomatic SVT of the lower limbs that was at least 5 cm on compression ultrasonography.
Incidence of venous thromboembolism and extension or recurrence of SVT in patients with isolated SVT at presentation.
Among 844 patients with SVT at inclusion (median age, 65 years; 547 women), 210 (24.9%) also had deep venous thrombosis (DVT) or symptomatic pulmonary embolism. Among 600 patients without DVT or pulmonary embolism at inclusion who were eligible for 3-month follow-up, 58 (10.2%) developed thromboembolic complications at 3 months (pulmonary embolism, 3 [0.5%]; DVT, 15 [2.8%]; extension of SVT, 18 [3.3%]; and recurrence of SVT, 10 [1.9%]), despite 540 patients (90.5%) having received anticoagulants. Risk factors for complications at 3 months were male sex, history of DVT or pulmonary embolism, previous cancer, and absence of varicose veins.
The findings are from a specialist referral setting, and the study was terminated before the target patient population was reached because of slow recruitment.
A substantial number of patients with SVT exhibit venous thromboembolism at presentation, and some that do not can develop this complication in the subsequent 3 months.
GlaxoSmithKline, sanofi-aventis, and the Ministère Français de la Santé et des Sports (Programme Hospitalier de Recherche Clinique).
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only